Loading clinical trials...

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections | Clinical Trials | Clareo Health

COMPLETEDNA

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

NCT01037192•Fraser Health

View on ClinicalTrials.gov

Summary

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

Eligibility

Age

19 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age 19 to 70 years
•Weight 40 - 80 kg
•Suspected or confirmed skin or soft tissue infection for which vancomycin is indicated
•Subject referred to or admitted into OPAT by an Infectious Disease Specialist or Emergency Physician
•Subject able to provide informed consent

Exclusion Criteria

•Known history of allergy to vancomycin
•Pregnancy
•Granulocytopenia (\< 1x109/L)
•Renal impairment (serum creatinine \> 177 µmol/L or eGFR \< 50 mL/min)
•Known history of vestibular disease or hearing loss
•Subjects treated with vancomycin within the previous month
•Subjects who have received more than 24 hours of vancomycin
•Subjects receiving other antimicrobials that cover MRSA (e.g. cotrimoxazole, rifampin, linezolid)

Locations (1)

Royal Columbian Hospital

New Westminster, British Columbia, Canada

Key Dates

Start Date

March 1, 2010

Primary Completion Date

September 1, 2010

Completion Date

September 1, 2010

Last Updated

August 27, 2015

Enrollment

ACTUAL participants

Conditions

Skin and Soft Tissue Infections

Interventions

vancomycin

DRUG

vancomycin

DRUG

The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

NCT01076049

Skin and Soft Tissue InfectionsAbscess

View study

COMPLETEDPHASE1

Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

NCT00989872

Skin and Soft Tissue InfectionsMethicillin-resistant Staphylococcus Aureus

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 27, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions